Navigation Links
Autism Consortium members publish in PNAS: Mechanism, treatment for Rett syndrome -- top cause autism girls
Date:2/9/2009

he IGF1 signaling axis may present a useful therapeutic strategy that could ultimately be translated to humans," said Dr. Antony Horton, Chief Scientific Officer at the International Rett Syndrome Foundation. "We are encouraged by this collaboration between scientists and clinicians which is yielding valuable insights into potential new treatments for Rett syndrome."

About Rett Syndrome and the Findings

Rett Syndrome, a neurodevelopmental disorder mainly affecting girls and also the most common basis of autism in girls, is primarily caused by a sporadic mutation in the MECP2 gene on the X chromosome. The MECP2 gene makes a protein, also called MeCP2, believed to play a pivotal role in silencing, i.e. turning off the activity of other genes. The MECP2 mutation causes the regulatory mechanism to fail, which in turn causes other genes to function abnormally.

Rett is a genetic disorder of developmental arrest or failure of brain maturation. This is thought to occur when subsets of neurons and their connections (synapses) are disrupted during a very dynamic phase of brain development. Scientists have been investigating ways to reverse that arrest and therefore, turn brain activity back on.

By crossing into the brain and activating 'IGF1 signaling' IGF1 binds to its receptor and activates downstream molecules within neurons that make synapses mature. This activity in turn ends the developmental arrest thought to underlie the syndrome.

Using mutant mice in which MeCP2 is deleted, Sur and his co-authors demonstrated a major underlying mechanism for the disordersynapses in the brain remain immature and showed persistent, abnormal plasticity into adulthood.

"Our research is beginning to show that other forms of autism also have, as their basis, this persistent immaturity of synapses," said Sur. "As a result, an even more exciting and promising aspect of this work is the possibility that IGF1 or similar thera
'/>"/>

Contact: Kathryn Morris
kathryn@kmorrispr.com
845-635-9828
Autism Consortium
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Los Angeles Dodger Matt Kemp and Dave Stewart Top Celebrity List to Raise Funds for Autism
2. 2 Genes Implicated in Autism
3. ToysRUs, Inc. Expands Its Support of Autism Speaks
4. Maximum Potential Offers Affordable Training Course for Parents of Children with Autism
5. New study explores the relationship between preterm birth and autism spectrum disorder
6. Upcoming Packard/Stanford Autism Symposium a Catalyst for Collaboration among Researchers and Community
7. Talk About Curing Autism Receives $300,000 Grant From Pacific Life Foundation to Provide Services for Families Affected by Autism in Orange County
8. Autism Speaks Announces Yearlong Partnership With Thomas & Friends (TM) Live! On Stage: A Circus Comes To Town
9. Federal Members of Advisory Committee Block Vaccine-Autism Research, Defy Wishes of Its Own Scientists, Autism Community, and Congress
10. Saliva Test Could Indicate Autism
11. Tampa is Latest Recipient of Project Lifesaver Grant Funds Through The National Autism Association

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2009)...RNewswire/ -- The development of University Medica...d a milestone today with a "topping out" ceremony,...n at the new hospital that will replace University... http://www.newscom.com/cgi-bin/prnh/20091203/NY2...ers, tradition in which a steel beam carrying an e...
(Date:12/3/2009)...wire-Asia/ -- Long believed to provide a variety o...nt ingredients in global,cuisine, has seen increas... The timing of this ginger demand increase coin...e pressures in a way that has speculators wonderin...ysteria over garlic. Garlic, also,believed to have...
(Date:12/3/2009)...e-USNewswire/ -- The American Association of Homes...enate for passing Sen. Michael Bennet,s (D-Colo.) ...uaranteed benefits, and strengthens Medicare by ke...silver tsunami of retiring baby boomers fast appro...slation currently before Congress to address Medic...
(Date:12/3/2009)...ylureas, but each patient will be different, exper...ews) -- A class of drugs still taken by millions ...a higher risk of dying and heart failure than the ... Sulfonylureas, long a mainstay of diabetes treatm... of oral anti-diabetes drugs, but doctors said the...
(Date:12/3/2009)...arning of diabetes, cardiovascular disease, resear...y News) -- Pregnant women who develop gestational ...d risk for metabolic syndrome three months after t... glucose intolerance is less severe than gestation... of factors (including high blood pressure, obesit...
Breaking Medicine News(10 mins):Health News:'Topping Out' Ceremony Marks Milestone in Construction of University Medical Center of Princeton at Plainsboro 2Health News:'Topping Out' Ceremony Marks Milestone in Construction of University Medical Center of Princeton at Plainsboro 3Health News:'Topping Out' Ceremony Marks Milestone in Construction of University Medical Center of Princeton at Plainsboro 4Health News:Ginger Prices Could Skyrocket on H1N1 Fears 2Health News:Diabetes Drugs Go Head-to-Head in Study 2Health News:Diabetes Drugs Go Head-to-Head in Study 3Health News:Blood Sugar Intolerance May Predict Postpartum Ills 2
...ing" may be more appropriate in men with low-risk ... with surgery or radiation therapy, according to a...Ann Arbor. The results of the study conducte...ed that watchful waiting or "expectant management"...
...syrup diet sweeping through Britain and promoted b...llowers lose a stone in 10 days.// All over t...Natural Tree Syrup flying off the shelves after po...s and costs about ?39.99 per liter. It is taken mi...
... glioma cancer cells that share many characteristi... of brain cancers by promoting tumor blood vessel/...e deadly cancers, a research team reported in the ...rsity, the researchers found that a small subset o...
...e bright sunshine on a warm autumn day does more t...y to produce huge amounts of vitamin D. Often call...ly a vitamin at all, but rather a versatile hormon...verts vitamin D produced in the skin into the acti...
... new study at the University of Michigan Depressio...epression are not getting// any treatment nor are ...gns of milder depression. In the latest issue ...equate treatment -- medication, talk therapy, or b...
...IDS epidemic would grow rapidly unless eight count... high-risk groups with better HIV prevention// mea...More than 5.5 million people are infected with HIV...e 16th International AIDS Conference in Toronto, C...
Other Medicine News:Health News:Watchful Waiting Effective for Low Risk Prostate Cancer 2Health News:Cancer Stem Cells Could Hold Key to Brain Tumor Therapy 2Health News:Sunshine Vitamin for Prostate Cancer 2Health News:No therapy for most of the pregnant women with depression 2Health News:No therapy for most of the pregnant women with depression 3Health News:No therapy for most of the pregnant women with depression 4Health News:India Urged to Take Stringent Measures to Combat AIDS 2Health News:India Urged to Take Stringent Measures to Combat AIDS 3
(Date:12/3/2009)...NEW YORK, Dec. 3 Guidepoint Globa...nounced the launch of their Sleep Apnea Tracker, a...nd projects trends and market share in the worldwi...ker captures actual patient usage for 87 different... from 15 different equipment providers going back ...
(Date:12/3/2009)..., DOYLESTOWN, Pa., Dec. 3 /PRNewswire-FirstCall/...rporation, (Nasdaq: QGLY ) www.quigleyco.com an...valuation of its opportunities to develop prescrip...uded that it is in its best interests to focus pri... may include but are not limited to its Cold-EEZE&...
(Date:12/3/2009)..., FORT WORTH, Texas, Dec. 3 /PRNewswire-First...C Bulletin Board: WNDM), a rapidly growing provide...n agreement with the Health Industry Representativ...ndependent sales and marketing representative to m...ct within the U.S. ,, HIRA will market and sel...
Breaking Medicine Technology:Leading Primary Research Firm Guidepoint Global Announces Launch of Sleep Apnea Tracker 2Quigley CEO, Ted Karkus, Announces Phase One of 2010 Strategic Plan; Karkus Reports that the Primary Focus will be on Leveraging its OTC Platform; Company Aggressively Seeking Product Acquisitions and Line Extensions which Leverage its Distribution 2Quigley CEO, Ted Karkus, Announces Phase One of 2010 Strategic Plan; Karkus Reports that the Primary Focus will be on Leveraging its OTC Platform; Company Aggressively Seeking Product Acquisitions and Line Extensions which Leverage its Distribution 3Wound Management Technologies, Inc. Signs Agreement with Major Sales Representative Organization for Increased Marketing of CellerateRx(R); Third Quarter Sales Up 2Wound Management Technologies, Inc. Signs Agreement with Major Sales Representative Organization for Increased Marketing of CellerateRx(R); Third Quarter Sales Up 3Cooper Martin Unveils Innovative Stylish Recovery Clothing for Those with Limited Mobility 48188 1Cooper Martin Unveils Innovative Stylish Recovery Clothing for Those with Limited Mobility 48188 2Tolerx Presents Data at 69th Scientific Sessions of the American Diabetes Association 4562 1Tolerx Presents Data at 69th Scientific Sessions of the American Diabetes Association 4562 2Tolerx Presents Data at 69th Scientific Sessions of the American Diabetes Association 4562 3Researchers work to boost effectiveness of the flu vaccine 48184 1Researchers work to boost effectiveness of the flu vaccine 48184 2Researchers work to boost effectiveness of the flu vaccine 48184 3
...(Nasdaq: PCOP ), an innovator in the discovery an..., today announced that Schering-Plough has,initiat...ith PS948115, a,compound identified from the colla...s being evaluated as a potential treatment for res...illion milestone payment from,Schering-Plough as a...
...e and With Lipitor(R), in, Overweight or Obese P... HAYWARD, Calif., Sept. 25 Metabolex, Inc., a,bi... development of novel,therapeutics for diabetes an...t it has begun a 180-patient Phase 2 trial of MBX-...lesterol and triglycerides to assess the drug,s,ef...
Other Medicine Technology:Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate 2Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate 3Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate 4Metabolex Begins Phase 2 Trial of MBX-8025 for Treatment of Dyslipidemia 2
Optima III Noninsulated Allis Tooth Grasper, without ratchet
Optima III Noninsulated Duck-Bill Grasper, with ratchet
Uninsulated locking handle
Snap-In Snap-Out®-II Single Ring Handle, ratcheted, noninsulated handle, insulated shaft
Medicine Products: